You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

    SBC: FirstString Research, Inc            Topic: NIDDK

    Project Summary/Abstract According to the ADA, 25.8 million children and adults have diabetes. Diabetics have an increased risk of complications such as heart disease and are prone to impaired wound healing. A major cause of morbidity and hospitalizationis diabetic foot ulceration (DFUs) that may result in infection, gangrene, amputations requiring prolonged hospitalization, costly treatments, an ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds

    SBC: FirstString Research, Inc            Topic: 200

    DESCRIPTION provided by applicant According to the ADA million children and adults have diabetes Diabetics have an increased risk of complications such as heart disease and are prone to impaired wound healing A major cause of morbidity and hospitalization is diabetic foot ulceration DFUs that may result in infection gangrene amputations requiring prolonged hospitalization costly tr ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis

    SBC: Innovimmune Biotherapeutics Holding, LLC            Topic: NIAID

    DESCRIPTION provided by applicant There are unmet medical needs in the limited biologic therapeutics for adults with rheumatoid arthritis RA associated with $ billion annual US health care and societal costs These are due to inadequate efficacy prohibitive costs poor adherence and safety issues infections andamp malignancies Oral small molecule based therapies are warranted due to ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. The Potential to Immunocloak Renal Allografts

    SBC: BREONICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The focus of this project is a novel immunomodifying therapy that provides protection from early allograft rejection in the absence of the standard toxic systemic immunosuppressive drug regimens This novel therapy is a nano barrier membrane called NB LVF consisting of a matrix made of laminin vitrogen fibronectin and type IV collagen NB LVF is applied to ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Electrical System for Rapidly Detecting Viable Bacteria in Blood Culture

    SBC: TECHSHOT, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Background Each year in the US there are over Million Blood Cultures performed to determine the presence absence of viable microorganisms in the blood of patients suspected of having Blood Steam Infection BSI or Septicemia Current technology for Blood Cultures typically takes days to provide a result Our proposed system would enable the user to obt ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Synthetic microparticle malaria vaccine

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION provided by applicant This Phase II project will develop a novel synthetic microparticle vaccine for malaria using the T BT epitopes of the circumsporozoite CS protein of Plasmodium falciparum the causative agent of human malaria There is no approved vaccine for malaria a disease that causes up to million new infections and million deaths each year in the developing wor ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A serologic assay to measure successful Lyme borreliosis antibiotic therapy

    SBC: L2 DIAGNOSTICS LLC            Topic: R

    DESCRIPTION provided by applicant Lyme disease LD caused by the Ixodes tick borne spirochete Borrelia burgdorferi Bb is the most common vector borne disease in the United States Despite public health preventive measures the annual confirmed case incidence has risen to over the vast majority of which occur in the Northeast Disseminated infection causes disease in the skin heart ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Gene Based Therapy for Congestive Heart Failure P2 SBIR

    SBC: Nanocor Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Congestive heart failure is a major cause of morbidity and mortality in the United States. While progress in conventional treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new therapeutic approaches. It is now apparent that gene therapy has broader potential in diseases such as congestive he ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Peptide-coated skin substitutes for the treatment of burn injuries and wounds

    SBC: AFFINERGY, LLC            Topic: 300

    DESCRIPTION provided by applicant Burn injuries and chronic wounds present a significant burden to patients and the US healthcare system Each year in the US there are burns that require medical treatment and burn patients that require hospitalization The mortality rate associated with severe burns can be as high as with of patient deaths arising from infection In add ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. IGF::OT::IGF SBIR Topic 314 Phase II- 3D Human Tumor Co-culture System for Accurate Prediction of Clinical Efficacy.

    SBC: KIYATEC, LLC            Topic: NCI

    Not Available

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government